Management of advanced-stage neuroblastoma in a patient with 21-hydroxalase deficiency

Pediatr Int. 2013 Aug;55(4):e96-9. doi: 10.1111/ped.12093.

Abstract

A 2-year-old boy presented with a 21-hydroxylase deficiency, associated with advanced-stage neuroblastoma primarily occurring in the left adrenal gland. He required intensive chemotherapy with polypharmacy, followed by cord blood stem cell transplantation to treat the neuroblastoma. The precise adjustment of cortisol levels was crucial in this patient to prevent adrenal crisis. We administered hydrocortisone by continuous infusion while monitoring blood cortisol levels. As there are no published reports on the target cortisol levels for children, we used two control infants with advanced-stage neuroblastoma, also undergoing chemotherapy and cord blood stem cell transplantation, to guide the continuous hydrocortisone therapy. The daily dose of hydrocortisone during chemotherapy required about threefold the normal treatment to avoid adrenal insufficiency. Continuous hydrocortisone therapy is feasible for preventing adrenal crisis and this report may provide an effective management for hydrocortisone replacement in 21-hydroxylase-deficient patients undergoing chemotherapy and hematopoietic stem cell transplantation.

Keywords: 21-hydroxylase deficiency; cord blood stem cell transplantation; hydrocortisone; neuroblastoma.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Gland Neoplasms / diagnosis
  • Adrenal Gland Neoplasms / therapy*
  • Adrenal Hyperplasia, Congenital / complications*
  • Adrenal Hyperplasia, Congenital / diagnosis
  • Child, Preschool
  • Combined Modality Therapy
  • Follow-Up Studies
  • Humans
  • Male
  • Neuroblastoma / complications
  • Neuroblastoma / diagnosis
  • Neuroblastoma / therapy*
  • Peripheral Blood Stem Cell Transplantation / methods*
  • Tomography, X-Ray Computed

Supplementary concepts

  • Congenital adrenal hyperplasia due to 21 hydroxylase deficiency